Clinical Trial

Neural Circuit Mechanism of Inflammatory Bowel Disease Combined With Depression

Study acronym: NCMOIBDCWD
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2024 (before its estimated July 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to understand the effects of gut microbiota dysbiosis treatment in patients with inflammatory bowel disease (IBD) combined with depression. The main question it aims to answer is: Does fecal microbiota transplantation (FMT) improve depression symptoms in IBD patients by altering GABA levels in the medial prefrontal cortex? Participants already undergoing fecal microbiota transplantation (FMT) as part of their regular medical care for IBD and comorbid depression will undergo regular assessments of GABA levels, gut microbiota, and depression symptoms for the duration of the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-18.
Trial Details
NCT Number NCT06471894
Lead Sponsor LanZhou University
Conditions Inflammatory Bowel Diseases
Enrollment 100 participants
Start Date 2024-07-01
Primary Completion 2024-07-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-25